Cargando…

GIP receptor agonism blocks chemotherapy-induced nausea and vomiting

OBJECTIVE: Nausea and vomiting remain life-threatening obstacles to successful treatment of chronic diseases, despite a cadre of available antiemetic medications. Our inability to effectively control chemotherapy-induced nausea and vomiting (CINV) highlights the need to anatomically, molecularly, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borner, Tito, Reiner, Benjamin C., Crist, Richard C., Furst, C. Daniel, Doebley, Sarah A., Halas, Julia G., Ai, Minrong, Samms, Ricardo J., De Jonghe, Bart C., Hayes, Matthew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326744/ https://www.ncbi.nlm.nih.gov/pubmed/37245848 http://dx.doi.org/10.1016/j.molmet.2023.101743

Ejemplares similares

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
por: Borner, Tito, et al.
Publicado: (2021)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
por: Samms, Ricardo J., et al.
Publicado: (2022)

Impact of tumour burden on chemotherapy-induced nausea and vomiting.
por: Hursti, T. J., et al.
Publicado: (1996)

Single nuclei RNA sequencing of the rat AP and NTS following GDF15 treatment
por: Reiner, Benjamin C., et al.
Publicado: (2021)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
por: Costa, Alessia, et al.
Publicado: (2021)

Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Chemotherapy- and cancer-related nausea and vomiting
por: Warr, D.G.
Publicado: (2008)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

Sugammadex to prevent postoperative nausea and vomiting?
por: Kendall, Mark C., et al.
Publicado: (2018)

Postoperative nausea and vomiting
por: Moon, Young Eun
Publicado: (2014)

Severe Epigastric Pain with Nausea and Vomiting
por: Grigorian, Areg, et al.
Publicado: (2019)

Management of Patients With Chemotherapy-Induced Nausea and Vomiting
por: Barbour, Sally Yowell
Publicado: (2017)

Chemotherapy-Induced Nausea and Vomiting: Updates and Recommendations
por: Viale, Pamela Hallquist
Publicado: (2018)

Creation of a Peptide Antagonist of the GFRAL–RET Receptor Complex for the Treatment of GDF15-Induced Malaise
por: Borner, Tito, et al.
Publicado: (2023)

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
por: Mroz, Piotr A., et al.
Publicado: (2018)

Dextrose for post-operative nausea and vomiting prophylaxis
por: Castro-Alves, Lucas J, et al.
Publicado: (2018)

Comment on ‘risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy’
por: Tong, Wing H, et al.
Publicado: (2023)

Anticipatory nausea in cyclical vomiting
por: McRonald, Fiona E, et al.
Publicado: (2005)

Nausea in Specific Phobia of Vomiting
por: Höller, Yvonne, et al.
Publicado: (2013)

Distinction between Nausea and Vomiting
Publicado: (1813)

COVID‐19, nausea, and vomiting
por: Andrews, Paul L R, et al.
Publicado: (2020)

Nausea, Vomiting, and Noninflammatory Diarrhea
por: Bobak, David A., et al.
Publicado: (2015)

Elderly male with nausea and vomiting
por: Galletta, Gayle M.
Publicado: (2023)

Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis
por: Milliken, Brandon T., et al.
Publicado: (2021)

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
por: Olver, Ian N
Publicado: (2008)

Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting
por: Bhandari, Prasan R.
Publicado: (2012)

Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)

Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
por: Navari, Rudolph M.
Publicado: (2015)

Investigation of Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
por: Lavdaniti, Maria, et al.
Publicado: (2014)

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics
por: May, Megan Brafford, et al.
Publicado: (2016)

Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
por: Gyawali, Bishal, et al.
Publicado: (2016)

Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting
por: Rock, Erin M., et al.
Publicado: (2016)

Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting
por: Wang, Nan, et al.
Publicado: (2020)

Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
por: Ying, Zhixiong, et al.
Publicado: (2023)

Intractable nausea and vomiting as presenting manifestation of neuromyelitis optica
por: Jagtap, Sujit A., et al.
Publicado: (2013)

Peripherally restricted oxytocin is sufficient to reduce food intake and motivation, while CNS entry is required for locomotor and taste avoidance effects
por: Asker, Mohammed, et al.
Publicado: (2023)

Optimal management of nausea and vomiting of pregnancy
por: Ebrahimi, Neda, et al.
Publicado: (2010)

An Intriguing Cause of Intractable Nausea and Vomiting
por: Girotra, Mohit, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7s8rij4urfmrokldfbknh7sgvn